Drug Profile
Research programme: CD38 antibody therapeutics - Amorfix Life Sciences
Latest Information Update: 18 Dec 2014
Price :
$50
*
At a glance
- Originator Amorfix Life Sciences
- Developer ProMIS Neurosciences; QED Bioscience
- Class Monoclonal antibodies
- Mechanism of Action CD38 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Multiple myeloma
Most Recent Events
- 18 Dec 2014 Suspended for Multiple myeloma in Canada (Parenteral)
- 18 Jul 2012 Research programme is available for licensing as of 30 Apr 2012. http://www.amorfix.com
- 24 Jun 2010 Early research in Multiple myeloma in Canada (Parenteral)